Ipamorelin pulls the trigger. CJC-1295 keeps the signal on for 6-8 days.
CJC-1295 is a long-acting GHRH analog. One injection amplifies your body's GH pulses for nearly a week — raising baseline IGF-1, preserving the natural pulsatile release pattern, and working through a completely different receptor pathway than Ipamorelin. Synthetic HGH floods your system with a flat signal and suppresses your own production. CJC-1295 amplifies what's already there. Together with Ipamorelin, it's the most studied GH secretagogue combination in peptide research. Ceiling raised. Trigger pulled. Output amplified. Weekly injection.
CJC-1295
CJC-1295 DAC (Modified GHRH 1–29)
CJC-1295 (with DAC) is a modified GHRH analogue with a Drug Affinity Complex that extends its half-life from minutes to 6–8 days. It amplifies the body's own GH pulses — raising baseline IGF-1 and sustaining elevated GH levels — making it the most practical long-acting GH secretagogue for body recomposition protocols.
Technical details
- CAS number
- 863288-34-0
- Molecular formula
- C165H269N47O46
MECHANISM OF ACTION
CJC-1295 binds to and activates GHRH receptors on pituitary somatotrophs, stimulating GH release. The Drug Affinity Complex (DAC) modification — a lysine-maleimide linker — allows covalent binding to serum albumin, extending half-life from 30 minutes (native GHRH) to 6–8 days. Unlike exogenous GH, it preserves the natural pulsatile GH secretion pattern and does not suppress endogenous production. Combined with a GHSR agonist (Ipamorelin), it produces synergistic GH release via two independent receptor pathways.
RESEARCH HIGHLIGHTS
2–10 fold increase in mean GH concentrations sustained for 6+ days after single injection
IGF-1 levels elevated 1.5–3x above baseline for 9–11 days, dose-dependently
Pulsatile GH pattern preserved — DAC extension does not blunt peak secretion or produce constant flat GH levels
Synergistic GH release with GHRP-6 (GHSR agonist) — dual-pathway stimulation produces supra-additive effect
RESEARCH PROTOCOLS
For laboratory use only. Not medical advice.
Once-weekly dosing due to 6–8 day half-life. Combine with Ipamorelin 100–200mcg daily for amplified GH release. Administer in the evening on an empty stomach.
Most-used research dose range. Stack with Ipamorelin + AOD-9604 for full metabolic recomposition protocol. Monitor IGF-1 and fasting glucose at 6-week mark.
Twice-weekly creates sustained IGF-1 elevation. Assess IGF-1 bloods before escalating. Fasting glucose monitoring recommended. Reduce frequency if water retention becomes excessive.
PAIRS WELL WITH
ORDER
SAFETY & CONTRAINDICATIONS
- Active malignancy (IGF-1 elevation — contraindicated)
- Diabetic retinopathy (IGF-1 concern)
- Acromegaly or pituitary tumour history
- Pregnancy or breastfeeding
- Children and adolescents (open growth plates)
Most common: transient water retention in first 2 weeks (resolves), facial flushing near injection time, increased hunger, joint aches at higher doses. Rare: carpal tunnel syndrome symptoms with extended high-dose use. Blood glucose monitoring recommended in pre-diabetic subjects.
For research and laboratory use only. Not intended for human consumption. Not for diagnostic or therapeutic purposes.